Navigation Links
Advanced BioHealing Appoints Kevin C. O'Boyle as Chief Financial Officer
Date:12/10/2010

WESTPORT, Conn., Dec. 10, 2010 /PRNewswire/ -- Advanced BioHealing, Inc. (ABH), a leader in commercializing cell-based therapies and delivering on the promise of regenerative medicine, today announced the appointment of Kevin C. O'Boyle, as Senior Vice President and Chief Financial Officer.

(Photo:  http://photos.prnewswire.com/prnh/20101210/LA15604)

"We are pleased to welcome Kevin to our team as we continue to build a leading commercial regenerative medicine organization," said Kevin Rakin, Chairman and Chief Executive Officer for ABH. "Kevin has an outstanding track record as CFO of companies executing high-growth strategies, focused on both organic and external opportunities, and accessing the equity markets."

ABH has grown revenue from zero in 2006 to over $130 million in 2010 and today employs more than 350 professionals. These strong results are based on growing demand for its FDA-approved product Dermagraft® for the treatment of diabetic foot ulcers.

"I am excited about joining the exceptional team at Advanced BioHealing," said Mr. O'Boyle. "Advanced BioHealing is a well-established leader in the field of regenerative medicine with the ability to improve patient lives with its cell-based therapy. I look forward to bringing my leadership experience to the company as it moves into its next phase of commercial growth."

Mr. O'Boyle has 15 years experience in the healthcare industry. From January 2003 until December 2009, Mr. O'Boyle served as the Chief Financial Officer of NuVasive, Inc., a medical device company focused on spinal applications, which completed its initial public offering in May 2004. He joined NuVasive when it had less than $30 million in annual revenue and was a key member of the management team that grew the business to more than $400 million in annual revenue. Prior to that time, Mr. O'Boyle served in various positions during his six years with ChromaVision Medical Systems, Inc., a publicly-held medical device company specializing in the oncology market, including as its Chief Financial Officer and Chief Operating Officer. Mr. O'Boyle currently serves on the boards of GenMark Diagnostics, Inc., a publicly traded molecular diagnostics company, and Tornier, BV, a privately held global orthopedics company.

Mr. O'Boyle received his Bachelor of Science in Accounting from the Rochester Institute of Technology and successfully completed the Executive Management Program at the University of California Los Angeles, John E. Anderson Graduate Business School.

About Advanced BioHealing, Inc.Advanced BioHealing develops and commercializes living cell therapies that repair damaged human tissue and enable the body to heal itself. A privately held company, Advanced BioHealing maintains its corporate office in Westport, Conn. with additional sites in La Jolla, Calif. and Nashville, Tenn. To learn more about Advanced BioHealing, please visit the Company's web site at www.ABH.com. Media Contacts: Lindsey Hart Advanced BioHealing lhart@abh.comDirect: (615) 250-3311Cell: (206) 335-0114 Marites CristobalEdelmanmarites.cristobal@edelman.comDirect: (323) 202-1424Cell: (415) 819-2214
'/>"/>

SOURCE Advanced BioHealing, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
2. New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations
3. Boehringer Ingelheim Initiates Phase III Clinical Trial With Afatinib in Advanced Breast Cancer
4. Data from Phase 2 Study of Alder Biopharmaceuticals Anti-IL-6 Antibody Therapeutic, ALD518, Demonstrate Reversal of Anemia in Patients with Advanced Non-Small Cell Lung Cancer
5. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
6. US FDA Advisory Committee Makes Recommendation on New Drug Application for Vandetanib in Advanced Medullary Thyroid Cancer
7. Dawson James Initiates Research Coverage of Advanced Life Sciences
8. Advanced Life Sciences Applies for FDA Orphan Drug Designation for ALS-886 to Treat Acute Lung Injury
9. New Stereotactic Body Radiation Therapy (SBRT) Protocols Fuel Interest in Advanced Lung and Liver Treatments
10. Published Results Show Denosumab Superior to Zometa® in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer
11. Advanced Life Sciences to Host 2010 Third Quarter Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... (NYSE: DVA ) today announced results for the ... Net income attributable to DaVita Inc. for the quarter and ... per share and $880 million, or $4.29 per share, respectively. ... for the quarter and year ended December 31, 2016, excluding ... per share, and $789 million, or $3.85 per share, respectively. ...
(Date:2/16/2017)... ST. LOUIS , Feb. 16, 2017  Express Scripts (NASDAQ: ... one of the World,s Most Admired Companies within the Health Care: ... to be named one of the World,s Most Admired Companies," said ... is driven by the commitment and passion of our 26,000 employees ... people we serve." ...
(Date:2/16/2017)... Research and Markets has announced the addition of the "Global ... Cancer Type, Technology - Forecast to 2025" report to their ... The ... a CAGR of around 28.6% over the next decade to reach ... the prominent trends that the market is witnessing include increasing demand ...
Breaking Medicine Technology:
(Date:2/18/2017)... (PRWEB) , ... February 18, 2017 , ... ... today provides the latest information and contact points to easily connect elderly veterans ... care, assisted living, and elder-care funding. It also conveys material on this year's ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... for the electronic prescribing of controlled and non-controlled substances plus the ability to ... pharmacies in the United States now accept electronic prescriptions, according to the Office ...
(Date:2/17/2017)... Church, VA (PRWEB) , ... February 17, 2017 ... ... Implementing the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, ... , Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? ...
(Date:2/17/2017)... Austin, Tx (PRWEB) , ... February 17, 2017 ... ... of revenue cycle management services, announced today that Karen Pilley has been promoted ... expenses is critical in today’s shifting healthcare paradigm – a shift that demands ...
(Date:2/17/2017)... ... February 17, 2017 , ... Like most hospitals across the nation, Onslow ... part by the Hospital Readmission Reduction Program (HRRP), the return of a patient to ... hospitals across the nation. While many providers are struggling to leverage limited resources and ...
Breaking Medicine News(10 mins):